Literature DB >> 15029469

Sleep-promoting properties of quetiapine in healthy subjects.

Stefan Cohrs1, Andrea Rodenbeck, Zhenghua Guan, Kathrin Pohlmann, Wolfgang Jordan, Andreas Meier, Eckart Rüther.   

Abstract

The aim of this study was to investigate the effects of quetiapine, an atypical antipsychotic, on polysomnographic sleep structure and subjective sleep quality. This double-blind, placebo-controlled, randomized cross-over study investigated the polysomnographic sleep structure and subjective sleep quality of 14 healthy male subjects given placebo, quetiapine 25 mg or quetiapine 100 mg. Volunteers were studied 3 times for 3 consecutive nights (N0, adaptation; N1, standard sleep conditions; N2, acoustic stress) 4 days apart. Treatment was administered orally 1 h before bedtime on nights 1 and 2. Quetiapine 25 mg and 100 mg significantly improved sleep induction and continuity under standard and acoustic stress conditions. Increases in total sleep time, sleep efficiency, percentage sleep stage 2 and subjective sleep quality were seen. A significant increase in periodic leg movements during sleep was observed with quetiapine 100 mg. The sleep-improving properties of quetiapine may be important in counteracting different aspects of psychopathology in schizophrenia and other disorders. These sleep-inducing and sleep-modifying properties are probably related to quetiapine's receptor-binding profile, including its antihistaminergic, antidopaminergic and antiadrenergic properties. Other mechanisms might be relevant as well and further investigation is required.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15029469     DOI: 10.1007/s00213-003-1759-5

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  45 in total

1.  Periodic leg movements in sleep and restless legs syndrome probably caused by olanzapine.

Authors:  T Kraus; A Schuld; T Pollmächer
Journal:  J Clin Psychopharmacol       Date:  1999-10       Impact factor: 3.153

2.  Effects of clozapine on sleep: a longitudinal study.

Authors:  D Hinze-Selch; J Mullington; A Orth; C J Lauer; T Pollmächer
Journal:  Biol Psychiatry       Date:  1997-08-15       Impact factor: 13.382

3.  Olanzapine acute administration in schizophrenic patients increases delta sleep and sleep efficiency.

Authors:  R J Salin-Pascual; M Herrera-Estrella; L Galicia-Polo; M R Laurrabaquio
Journal:  Biol Psychiatry       Date:  1999-07-01       Impact factor: 13.382

4.  Effect of neuroleptic treatment on polysomnographic measures in schizophrenia.

Authors:  S F Taylor; R Tandon; J E Shipley; A S Eiser
Journal:  Biol Psychiatry       Date:  1991-11-01       Impact factor: 13.382

5.  Antagonizing the effects of experimentally induced sleep disturbance in healthy volunteers by lormetazepam and zolpidem.

Authors:  R Cluydts; J De Roeck; P Cosyns; P Lacante
Journal:  J Clin Psychopharmacol       Date:  1995-04       Impact factor: 3.153

6.  Effects of clozapine on sleep measures and sleep-associated changes in growth hormone and cortisol in patients with schizophrenia.

Authors:  J H Lee; J I Woo; H Y Meltzer
Journal:  Psychiatry Res       Date:  2001-09-20       Impact factor: 3.222

7.  Epidemiology of prescriptions for neuroleptic drugs: tranquilizers rather than antipsychotics.

Authors:  M Linden; C Thiels
Journal:  Pharmacopsychiatry       Date:  2001-07       Impact factor: 5.788

8.  Restless legs syndrome probably induced by risperidone treatment.

Authors:  T C Wetter; J Brunner; T Bronisch
Journal:  Pharmacopsychiatry       Date:  2002-05       Impact factor: 5.788

Review 9.  Clinical use of quetiapine in disease states other than schizophrenia.

Authors:  S Charles Schulz
Journal:  J Clin Psychiatry       Date:  2002       Impact factor: 4.384

10.  Risperidone augmentation decreases rapid eye movement sleep and decreases wake in treatment-resistant depressed patients.

Authors:  Ann L Sharpley; Zubin Bhagwagar; Sepehr Hafizi; W Richard Whale; Harm J Gijsman; Philip J Cowen
Journal:  J Clin Psychiatry       Date:  2003-02       Impact factor: 4.384

View more
  35 in total

Review 1.  Drug-induced sleep: theoretical and practical considerations.

Authors:  Jeffrey M Ellenbogen; Edward F Pace-Schott
Journal:  Pflugers Arch       Date:  2011-09-28       Impact factor: 3.657

2.  Antidepressant and Antipsychotic Drugs.

Authors:  Andrew D Krystal
Journal:  Sleep Med Clin       Date:  2010-12-01

Review 3.  Treatment options for sleep disturbances during alcohol recovery.

Authors:  J Todd Arnedt; Deirdre A Conroy; Kirk J Brower
Journal:  J Addict Dis       Date:  2007

4.  Quetiapine in primary insomnia: a pilot study.

Authors:  Michael H Wiegand; Florentina Landry; Torsten Brückner; Corina Pohl; Zdenko Veselý; Thomas Jahn
Journal:  Psychopharmacology (Berl)       Date:  2007-10-06       Impact factor: 4.530

5.  Novel Pharmacologic Approaches to Treating Cannabis Use Disorder.

Authors:  Rebecca E Balter; Ziva D Cooper; Margaret Haney
Journal:  Curr Addict Rep       Date:  2014-06-01

6.  Differential mechanisms underlie the regulation of serotonergic transmission in the dorsal and median raphe nuclei by mirtazapine: a dual probe microdialysis study.

Authors:  Kouji Fukuyama; Shunske Tanahashi; Tatsuya Hamaguchi; Masanori Nakagawa; Takashi Shiroyama; Eishi Motomura; Motohiro Okada
Journal:  Psychopharmacology (Berl)       Date:  2013-05-09       Impact factor: 4.530

7.  Periodic Leg Movements in Sleep and Restless Legs Syndrome: Considerations in Geriatrics.

Authors:  Donald L Bliwise
Journal:  Sleep Med Clin       Date:  2006-06-01

Review 8.  Psychiatric disorders and sleep.

Authors:  Andrew D Krystal
Journal:  Neurol Clin       Date:  2012-11       Impact factor: 3.806

Review 9.  [Restless legs syndrome, periodic limb movements, and psychopharmacology].

Authors:  S Cohrs; A Rodenbeck; M Hornyak; D Kunz
Journal:  Nervenarzt       Date:  2008-11       Impact factor: 1.214

10.  [Disturbances of slow-wave sleep and psychiatric disorders].

Authors:  J P Doerr; V Hirscher; D Riemann; U Voderholzer
Journal:  Nervenarzt       Date:  2010-03       Impact factor: 1.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.